Oral presentation to highlight preclinical
investigation of Claudin-6 ADC in ovarian and NSCLC cancer
models
Preclinical data for PSMA and ASCT2-targeted
ADCs accepted for poster presentations
LAUSANNE, Switzerland, March 25,
2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE:
ADCT), a commercial-stage global leader and pioneer in the field of
antibody drug conjugates (ADCs), today announced abstracts
detailing multiple preclinical programs have been accepted for
presentation at the American Association for Cancer Research (AACR)
Annual Meeting 2025, taking place April
25-30, 2025, in Chicago,
Illinois.
"We are excited to present preclinical data on our
exatecan-based Claudin-6, PSMA, and ACST2-targeting antibody-drug
conjugates," said Patrick van
Berkel, PhD, Chief Scientific Officer of ADC Therapeutics.
"These ADCs hold promise for targeted cancer treatment in a broad
range of cancer types, and we are pleased to have the opportunity
to share our learnings across select solid tumors where there
remains unmet need."
Details of ADC Therapeutics' oral presentation at AACR are as
follows:
Title: Preclinical investigation of ADCT-242, a novel
exatecan-based antibody drug conjugate targeting Claudin-6, as
single agent or in combination in ovarian and non-small lung cancer
models
Abstract: 1163
Session Category: Experimental and Molecular
Therapeutics
Session Title: Antibody-Based Cancer Therapeutic Agents
Date and Time: Sunday, April 27,
2025, 3:00-5:00 p.m. CT
Presenter: Chris Pickford,
Head of Clinical Research, ADC
Therapeutics
Details of ADC Therapeutics' poster presentations at AACR are as
follows:
Title: Preclinical Development of ADCT-241, a Novel
Exatecan-based Antibody-Drug Conjugate Targeting PSMA for the
Treatment of Prostate Cancer
Abstract: 6736
Session Category: Experimental and Molecular
Therapeutics
Session Title: Antibody-Based Cancer Therapeutics 4
Date and Time: Wednesday, April 30,
2025, 9:00 a.m. – 12:00 p.m. CT
Presenter: Ben Leatherdale,
Senior Scientist, ADC
Therapeutics
Title: HuB14-VA-PL2202, a novel antibody-drug conjugate
targeting ASCT2, a novel ADC target over-expressed in both solid
and hematological cancers
Abstract: 1580
Session Category: Experimental and Molecular
Therapeutics
Session Title: Antibody-Based Cancer Therapeutics 1
Date and Time: Monday, April 28,
2025, 9:00 a.m. – 12:00 p.m. CT
Presenter: Danilo Cucchi,
Senior Scientist, ADC
Therapeutics
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage global
leader and pioneer in the field of antibody drug conjugates (ADCs).
The Company is advancing its proprietary ADC technology to
transform the treatment paradigm for patients with hematologic
malignancies and solid tumors.
ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab
tesirine-lpyl) received accelerated approval by the FDA and
conditional approval from the European Commission for the treatment
of relapsed or refractory diffuse large B-cell lymphoma after two
or more lines of systemic therapy. ZYNLONTA is also in development
in combination with other agents and in earlier lines of therapy.
In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in
development.
ADC Therapeutics is based in Lausanne (Biopôle), Switzerland, and has operations in
London and New Jersey. For more information, please visit
https://adctherapeutics.com/ and follow the Company on
LinkedIn.
ZYNLONTA® is a registered trademark of ADC
Therapeutics SA.
Forward-Looking Statements
This press release contains
forward-looking statements within the meaning of the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
In some cases you can identify forward-looking statements by
terminology such as "may", "will", "should", "would", "expect",
"intend", "plan", "anticipate", "believe", "estimate", "predict",
"potential", "seem", "seek", "future", "continue", or "appear" or
the negative of these terms or similar expressions, although not
all forward-looking statements contain these identifying words.
Forward-looking statements are subject to certain risks and
uncertainties that can cause actual results to differ materially
from those described. Factors that may cause such differences
include, but are not limited to: the timing and future results of
the Company's early research in exatecan-based Claudin-6, PSMA and
ASCT2-targeting antibody-drug conjugates; the expected cash runway
into mid-2026 the Company's ability to grow
ZYNLONTA® revenue in the
United States; the ability of our partners to commercialize
ZYNLONTA® in foreign markets, the timing and amount
of future revenue and payments to us from such partnerships and
their ability to obtain regulatory approval for
ZYNLONTA® in foreign jurisdictions; the timing and
results of the Company's or its partners' research and development
projects or clinical trials including LOTIS
5 and 7 and ADCT 602; the timing and results of
investigator-initiated trials including those studying FL and MZL
and the potential regulatory and/or compendia strategy and the
future opportunity; the timing and outcome of regulatory
submissions for the Company's products or product candidates;
actions by the FDA or foreign regulatory authorities; projected
revenue and expenses; the Company's indebtedness, including
Healthcare Royalty Management and Blue Owl and Oaktree facilities,
and the restrictions imposed on the Company's activities by such
indebtedness, the ability to comply with the terms of the various
agreements and repay such indebtedness and the significant cash
required to service such indebtedness; and the Company's ability to
obtain financial and other resources for its research, development,
clinical, and commercial activities. Additional information
concerning these and other factors that may cause actual results to
differ materially from those anticipated in the forward-looking
statements is contained in the "Risk Factors" section of the
Company's Annual Report on Form 10-K and in the Company's other
periodic and current reports and filings with the U.S. Securities
and Exchange Commission. These statements involve known and unknown
risks, uncertainties and other factors that may cause actual
results, performance, achievements or prospects to be materially
different from any future results, performance, achievements or
prospects expressed in or implied by such forward-looking
statements. The Company cautions investors not to place undue
reliance on the forward-looking statements contained in this
document.
CONTACTS:
Investors
Marcy
Graham
ADC Therapeutics
Marcy.Graham@adctherapeutics.com
+1 650-667-6450
Media
Nicole Riley
ADC Therapeutics
Nicole.Riley@adctherapeutics.com
+1 862-926-9040
View original content to download
multimedia:https://www.prnewswire.com/news-releases/adc-therapeutics-announces-abstracts-accepted-for-presentation-at-the-american-association-for-cancer-research-annual-meeting-2025-302411310.html
SOURCE ADC Therapeutics SA
